Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.83 |
| ▸ | TP53 | P04637 | 4/20 | 0.83 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24335036 | 0.88 | PTGS2 (0.83) | MAPTTP53PTGS2PTGS1ADORA2A | |
| SCHEMBL5787610 | 0.88 | PTGS2 (1.00) | MAPTTP53PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL5785800 | 0.87 | PTGS2 (1.00) | MAPTTP53PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL5788345 | 0.86 | PTGS2 (0.81) | MAPTTP53PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL5787875 | 0.80 | PTGS2 (0.78) | MAPTTP53PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL4721120 | 0.79 | PTGS1 (0.83) | TP53PTGS2PTGS1SMN1; SMN2KDM4E | |
| SCHEMBL5315322 | 0.79 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL19805682 | 0.77 | NPSR1 (1.00) | MAPTTP53PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL5787163 | 0.77 | PTGS2 (0.73) | TP53PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL5791089 | 0.76 | PTGS2 (0.66) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254119-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | claimed |
| US-6780870-B2 | TREATMENT OF THE PAIN (BOTH CHRONIC AND ACUTE), FEVER AND INFLAMMATION OF A VARIETY OF CONDITIONS AND DISEASES MEDIATED BY COX-2 | SMITHKLINE BEECHAM CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20030109538-A1 | Pyrmidine derivatives as selective inhibitors of cox-2 | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | claimed |
| EP-1254119-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-11-06 | — | — | EP | claimed |
| WO-2001058881-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-08-16 | — | — | WO | claimed |
| EP-1254119-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-6780870-B2 | TREATMENT OF THE PAIN (BOTH CHRONIC AND ACUTE), FEVER AND INFLAMMATION OF A VARIETY OF CONDITIONS AND DISEASES MEDIATED BY COX-2 | SMITHKLINE BEECHAM CORPORATION | 2004-08-24 | — | — | US | disclosed |
| US-20030109538-A1 | Pyrmidine derivatives as selective inhibitors of cox-2 | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1254119-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058881-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109538-A1 | Pyrmidine derivatives as selective inhibitors of cox-2 | PTGS1, PTGS2, PTGES2 | MAPT 4113/4885TP53 4715/4885PTGS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.